CANCER

Cancer and the gut microbiota: An unexpected link
Laurence Zitvogel,1,2† Lorenzo Galluzzi,1,3,4,5,6 Sophie Viaud,1,2 Marie Vétizou,1,2 Romain Daillère,1,2 Miriam Merad,4 Guido Kroemer1,3,4,5,7,8

Changes in the interactions among the gut microbiota, intestinal epithelium, and host immune system are associated with many diseases, including cancer. We discuss how environmental factors influence this cross-talk during oncogenesis and tumor progression and how manipulations of the gut microbiota might improve the clinical activity of anticancer agents.

One hundred trillion organisms (mainly bacteria) collectively referred to as the gut microbiota colonize the human intestine. Reflecting a notable degree of coevolution, the gut microbiota thrives in mutually advantageous equilibrium with the host (eubiosis). The intestine offers a protected, warm, and nutrient-rich microenvironment to resident microbes, while the gut microbiota assists humans in the digestion of complex carbohydrates, provides them with non-nutrient essential factors, and occupies ecological niches that might otherwise be colonized by pathogenic microorganisms (1). The immune system tolerates the normal gut microbiota while ensuring immunosurveillance against invading pathogens. Moreover, accumulating evidence indicates that the proper development of both intestinal and extraintestinal components of the immune system requires the gut microbiota (2). In this Perspective, we discuss how disequilibria in the intimate relationship between the host and intestinal bacteria (dysbiosis) affect oncogenesis, tumor progression, and response to cancer therapy and how the gut microbiota may be manipulated for therapeutic purposes. A detailed description of the intestinal immune system is beyond the scope of this article and can be found in (2).

DYSBIOSIS AND CARCINOGENESIS
Dysbiosis can be caused not only by pathogenic organisms and passenger commensals but also by aging and environmental factors such as antibiotics, xenobiotics, smoking, hormones, and dietary cues (1); these are also well-established risk factors for the development of intestinal or extraintestinal neoplasms. In addition, genetic defects that affect epithelial, myeloid, or lymphoid components of the intestinal immune system favor dysbiosis because they promote inflammatory states, such as Crohn’s disease, that increase the host’s risk for neoplastic transformation (3). Thus, several factors that favor carcinogenesis also promote dysbiosis.

Epidemiological studies that link intra-abdominal infections, the use of antibiotics, or both to an increased incidence of colorectal cancer (4) underscore the clinical importance of the association between dysbiosis and intestinal carcinogenesis. In fact, the gut microbiota affects colorectal carcinogenesis by various mechanisms. Abrogating or specifically altering the composition of the gut microbiota influences the incidence and progression of colorectal carcinoma in both genetic and carcinogen-induced models of tumorigenesis (5–7). Moreover, several by-products of the gut microbiota directly target intestinal epithelial cells (IECs) and either mediate oncogenic effects (as reported for hydrogen sulfide and the Bacteroides fragilis toxin) or suppress tumorigenesis (as demonstrated for short-chain fatty acids) (8).

Intestinal bugs participate in more than just colorectal carcinogenesis. Experimental alterations of the gut microbiota also influence the incidence and progression of extraintestinal cancers, including breast and hepatocellular carcinoma, presumably through inflammatory and metabolic circuits (9, 10). These results are compatible with the findings of epidemiological studies that reveal an association between dysbiosis, its consequences or determinants (in particular the overuse of antibiotics), and an increased incidence of extracolonic neoplasms, including breast carcinoma (11, 12). These findings may reflect the systemic distribution of bacteria and their by-products in the course of inflammatory responses that compromise the integrity of the intestinal barrier (9).

Thus, the gut microbiota influences oncogenesis and tumor progression both locally and systemically. Although inflammatory and metabolic cues support this phenomenon, additional, hitherto uncharacterized mechanisms can contribute to the ability of dysbiosis to promote carcinogenesis (Fig. 1).

RELATIONSHIP STATUS: IT’S COMPLICATED
During cancer therapy, the gut microbiota and antineoplastic agents interact in a bidirectional fashion. On the one hand, several interventions currently used for the management of neoplastic diseases exert cytotoxic effects on intestinal bacteria, de facto promoting dysbiosis (13). Thus, radiation therapy, allogeneic stem cell transplantation, and several chemotherapeutic agents such as irinotecan (a topoisomerase I inhibitor licensed for the treatment of colorectal carcinoma) and 5-fluorouracil (a nucleoside analog used against several carcinomas) can be toxic for the gut microbiota—and hence alter its composition—either directly or by activating an immune response (14–16). Moreover, these (and other) therapeutic interventions exert unwarranted side effects on the intestinal barrier (table S1). On the other hand, accumulating evidence indicates that the gut microbiota influences both the therapeutic activity and the side effects of anticancer agents, via pharmacodynamic (17, 18) and immunological mechanisms (19, 20) (Fig. 2).

Pharmacodynamic effects. By virtue of their abundance and pronounced metabolic activity, intestinal bacteria can determine the bioavailability and biological effects, be they warranted (efficacy) or not (toxicity), of ingested xenobiotics. This has been demonstrated for several drugs, including irinotecan (17, 18). The dose-limiting diarrhea associated with irinotecan has been attributed to the ability of the gut microbiota to reactivate the drug locally (17). Moreover,
the gastrointestinal toxicity of irinotecan is reduced by the administration of a Chinese herbal medicine (PHY906) that acquires the ability to stimulate the regeneration of intestinal progenitor cells only upon transformation by bacterial β-glucuronidase (which is highly expressed by the gut microbiota) (18).

The effects of the gut microbiota on the pharmacodynamics of anticancer agents may not be limited to orally administered molecules (which physically get in contact with intestinal bacteria), but may involve systemic interventions. Indeed, germ-free (GF) mice have been reported to differ from their conventional, pathogen-free counterparts in the expression of a broad panel of hepatic genes involved in xenobiotic metabolism (21). Moreover, the gut microbiota may play a critical role in the elicitation of acute graft-versus-host disease (GVHD), a critical obstacle against the clinical success of allogeneic stem cell transplantation. Several reports link dysbiosis (most often characterized by an enrichment in Enterobacteriaceae spp.) to overt infections and intestinal GVHD, with a major role for Paneth cell destruction and alterations in the TLR9/MYD88 signaling axis (15, 22). Thus, besides influencing the gastrointestinal side effects of some anticancer interventions, dysbiosis may undermine their therapeutic activity. Conversely, a eubiotic gut microbiota may limit the unwarranted side effects of various antineoplastic agents.

**Immunological effects.** Accumulating evidence indicates that the gut microbiota also modulates the response of several tumor types to cancer therapy via immunological circuitries, at least in mice (19, 20, 23). For example, lymphodepleting total body irradiation reportedly promotes the translocation of the gut microbiota or at least some of its components or products across the intestinal epithelium. This not only correlates with increased dendritic cell activation and elevated levels of blood-borne proinflammatory cytokines but also contributes to the ability of irradiation to maximize the efficacy of adoptively transferred CD8+ T lymphocytes (23). Accordingly, antibiotic-treated mice, mice injected with a lipopolysaccharide (LPS)–neutralizing antibody, as well as Cd14−/− and Trlr4−/− mice (which do not respond to LPS normally) are less sensitive to lymphodepleting irradiation than are their control counterparts (23).

The injection of cyclophosphamide (an immunostimulatory alkylation agent used against multiple carcinomas) into mice maintained in pathogen-free conditions promotes mucosal injury and translocation of specific Gram-positive bacteria across the intestinal epithelium (20). This phenomenon was linked to therapeutically relevant T helper type 1 (Th1) and Th17 immune responses in the spleen (20). GF and antibiotic-treated tumor-bearing mice, which failed to mount such antibacterial T cell–mediated responses, were more resistant than their control counterparts to the therapeutic effects of cyclophosphamide (20). Moreover, the full-blown antineoplastic activity of cyclophosphamide could be restored in antibiotic-treated mice upon the adoptive transfer of Th17 cells established and propagated in vitro (20). However, not all Gram-positive bacteria were able to elicit beneficial Th17 immune responses in this setting. Rather, specific prokaryotes such as *Parabacteroides distasonis* [which exerts regulatory T (Treg) cell–stimulatory effects] and segmented filamentous bacteria (which trigger conventional Th17 responses) reduced the beneficial effects of anticancer chemotherapy.

Consistent with these data, a healthy gut microbiota has been shown to contribute to the therapeutic activity of a CpG oligodeoxynucleotide–based immunotherapeutic regimen and platinum derivatives (19). The gut microbiota influenced the propensity of CpG oligodeoxynucleotides combined with a monoclonal antibody that neutralizes
interleukin-10 receptor α (IL10RA) to elicit a therapeutically relevant, tumor necrosis factor–α (TNF-α)–dependent innate immune response against malignant cells. In addition, a eubiotic gut microbiota was necessary for oxaliplatin (an immunogenic platinum salt approved for use in colorectal cancer patients) to promote tumor infiltration by myeloid cells that mediated antineoplastic effects by producing reactive oxygen species (ROS) (19). In line with this notion, the chemotherapy-impairing effects of antibiotics could be mimicked by the Cybb−/− genotype (corresponding to the lack of a ROS-generating enzyme) as well as by the systemic administration of antioxidants (19). Mice lacking Myd88 or Tlr4 (encoding critical components of the machinery sensing microbe-associated molecular patterns) were also more resistant to oxaliplatin-based chemotherapy than were their wild-type counterparts (19). Thus, the full-blown therapeutic activity of oxaliplatin involves the detection of components of the gut microbiota by the immune system, allowing for the generation of tumor-infiltrating myeloid cells with antineoplastic activity.

Altogether, these observations indicate that anticancer therapy can promote two functionally opposite types of dysbiosis: detrimental dysbiosis, which limits the therapeutic efficacy or increases the toxicity of treatment, and beneficial dysbiosis, which is required for, or at least markedly improves, its clinical activity (Fig. 1). This suggests that the pharmacological manipulation of the gut microbiota holds great promise as an adjuvant to improve the therapeutic index of anticancer therapy.

**MANIPULATING THE MICROBIOTA FOR CANCER THERAPY**

At least hypothetically, four distinct measures can be used to alter the effects of the gut microbiota on anticancer therapy: (i) antibiotics, chemicals with a preferential cytotoxicity for one or more bacterial species; (ii) probiotics, living bacteria or other microorganisms that, when administered in adequate amounts, confer a health benefit; (iii) prebiotics, nondigestible compounds that stimulate the growth and/or functions of specific components of the gut microbiota; and (iv) postbiotics, nonviable products of the gut microbiota that exert biological activities in the host.

Using common antibiotics (which often target multiple types of Gram-positive or Gram-negative bacteria) to cause a state of dysbiosis that supports, rather than counteracts, the efficacy of chemotherapeutic agents may not be feasible because of specificity issues. However, it may be possible to use antibiotics to reverse a previously established state of detrimental dysbiosis (24). Recent data indicate that bacteriocins, proteinaceous antibiotics produced by some bacterial strains, may be harnessed to specifically deplete one or a few components of the gut microbiota for therapeutic purposes (1). Moreover, specific chemicals may be successfully used to limit the negative impact of the gut microbiota on the pharmacodynamics of specific chemotherapeutics. As a proof of principle, a potent inhibitor of bacterial (but not mammalian) β-glucuronidase has been shown to protect mice from the intestinal side effects of irinotecan, widening its therapeutic window (17).

Probiotics have been extensively tested in animal tumor models for their ability to prevent (mostly intestinal) carcinogenesis, with promising results (25, 26). Moreover, genetically modified probiotics have been successfully used as vectors for the delivery of tumor-associated antigens, immunostimulatory molecules, or enzymes that limit the toxicity of conventional chemotherapy, at least in animal models (27). Some of these approaches, notably anticancer vaccines based on live, attenuated variants of *Listeria monocytogenes* or *Salmonella enterica*, are currently being tested for their safety and ability to elicit therapeutically relevant immune responses in cancer patients (28), reflecting a considerable progress in the academic and industrial development of vaccines harnessing mucosal immunity (29).

Thus far, epidemiological studies have been unable to firmly establish whether probiotics can reduce the risk of developing colorectal carcinoma in specific patient populations (26). Similarly, clinical data on the use of probiotics as a means to limit the gastrointestinal toxicity of radiation therapy and some chemotherapeutics are insufficient to draw a firm conclusion on their actual benefits (30). Although prebiotics (such as inulin or oligofructose) and postbiotics (such as butyrate) have attracted attention as potential means of preventing colorectal cancer, the ability of these agents to widen the therapeutic window of chemotherapy remains poorly explored (31).

In view of the recent findings showing that specific alterations in the gut microbiota are instrumental, rather than detrimental, to the efficacy of anticancer chemotherapy, it is tempting to speculate that the clinical profile of at least some chemotherapeutics can be improved by combinatorial interventions relying on one or more antibiotics, prebiotics, probiotics, and/or postbiotics. This hypothesis urgently awaits experimental confirmation.

Accumulating evidence demonstrates that intestinal bacteria influence oncogenesis, tumor progression, and response to therapy. Thus, selectively manipulating the gut microbiota may represent a feasible means to (i) limit the incidence of specific tumors in the general population and/or (ii) improve the activity of various anticancer agents (32). Although the first possibility has been investigated in several models of oncogenesis with promising results, the actual oncopreventive effects of anti-, pre-, pro-, and postbiotics in humans remain to be established. Conversely, selectively manipulating the composition of the gut microbiota as a gateway to optimal responses to chemo-, radio-, or immunotherapy in the clinic is a relatively new concept, and additional studies are required to understand the clinical value of such an approach. In this context, the limited selectivity of most conventional antibiotics and the elevated interindividual heterogeneity of the gut microbiota may constitute major obstacles. Highly specific antimicrobials such as bacteriocins and the development of new technologies allowing for the rapid in-depth characterization of the gut microbiota on a personalized basis may circumvent these issues, at least in part. Modulating the gut microbiota may constitute a viable strategy for improving the clinical efficacy of anticancer chemo-, radio-, and immunotherapy.
Cancer and the gut microbiota: An unexpected link
Laurence Zitvogel, Lorenzo Galluzzi, Sophie Viaud, Marie Vétizou, Romain Daillère, Miriam Merad and Guido Kroemer (January 21, 2015)
Science Translational Medicine 7 (271), 271ps1. [doi: 10.1126/scitranslmed.3010473]

Editor's Summary

The following resources related to this article are available online at http://stm.sciencemag.org. This information is current as of April 14, 2016.

Article Tools
Visit the online version of this article to access the personalization and article tools:
http://stm.sciencemag.org/content/7/271/271ps1

Supplemental Materials
"Supplementary Materials"
http://stm.sciencemag.org/content/suppl/2015/01/20/7.271.271ps1.DC1

Related Content
The editors suggest related resources on Science's sites:
http://stm.sciencemag.org/content/scitransmed/6/263/263ra158.full
http://stm.sciencemag.org/content/scitransmed/6/252/252ra120.full
http://stm.sciencemag.org/content/scitransmed/6/237/237ra66.full
http://stm.sciencemag.org/content/scitransmed/4/137/137rv6.full
http://science.sciencemag.org/content/sci/349/6251/929.full
http://science.sciencemag.org/content/sci/349/6251/989.full
http://science.sciencemag.org/content/sci/349/6252/1058.full
http://science.sciencemag.org/content/sci/349/6252/1101.full
http://science.sciencemag.org/content/sci/349/6253/aac5992.full
http://science.sciencemag.org/content/sci/350/6264/1079.full
http://science.sciencemag.org/content/sci/350/6264/1084.full
http://science.sciencemag.org/content/sci/350/6264/1031.full
http://science.sciencemag.org/content/sci/349/6251/993.full
http://science.sciencemag.org/content/sci/349/6251/989.full
http://science.sciencemag.org/content/sci/349/6252/1058.full
http://science.sciencemag.org/content/sci/349/6252/1101.full
http://science.sciencemag.org/content/sci/349/6253/aac5992.full
http://science.sciencemag.org/content/sci/350/6264/1079.full
http://science.sciencemag.org/content/sci/350/6264/1084.full
http://science.sciencemag.org/content/sci/348/6230/80.full
http://science.sciencemag.org/content/sci/349/6251/993.full
http://science.sciencemag.org/content/sci/349/6251/989.full
http://science.sciencemag.org/content/sci/349/6252/1058.full
http://science.sciencemag.org/content/sci/349/6252/1101.full
http://science.sciencemag.org/content/sci/349/6253/aac5992.full
http://science.sciencemag.org/content/sci/350/6264/1079.full
http://science.sciencemag.org/content/sci/350/6264/1084.full
http://science.sciencemag.org/content/sci/348/6230/80.full
http://science.sciencemag.org/content/sci/350/6261/614.full

Permissions
Obtain information about reproducing this article:
http://www.sciencemag.org/about/permissions.dtl

Science Translational Medicine (print ISSN 1946-6234; online ISSN 1946-6242) is published weekly, except the last week in December, by the American Association for the Advancement of Science, 1200 New York Avenue, NW, Washington, DC 20005. Copyright 2016 by the American Association for the Advancement of Science; all rights reserved. The title Science Translational Medicine is a registered trademark of AAAS.